RxDoctor Payments Data

William George, DO

Psychiatry · Maywood, ILNPI 1295149797

Payments from drug & device makers

$7,929in general payments, 2019–2025

Across 125 payments — averaging $63.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Supernus Pharmaceuticals, Inc.$6K
  • Johnson & Johnson$533
  • Sunovion Pharmaceuticals Inc.$345
  • Otsuka America Pharmaceutical, Inc.$184
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$179
  • Teva Pharmaceuticals USA, Inc.$79
  • plus $391 from 7 others

What the payments were for

  • Speaking & faculty fees$4,62558%
  • Travel & lodging$94312%
  • Food & beverage$2,36030%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,929 in reported general payments places this provider in the 90th percentile of 1,344 psychiatry providers in Illinois.

See all psychiatry providers in Illinois

Medicare billing

Part B allowed, 2024
$42,092
Medicare patients
103
Services billed
388

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrintellixVortioxetine Hydrobromide15$7,979
Aripiprazole29$2,092
Quetiapine Fumarate86$1,300
Clozapine30$1,236
Clonazepam153$1,165
Alprazolam ErAlprazolam29$1,090
Prazosin Hcl54$935
Bupropion XlBupropion Hcl63$909
Divalproex Sodium ErDivalproex Sodium19$869
Duloxetine Hcl36$703
Bupropion Hcl SrBupropion Hcl35$530
Gabapentin40$525
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine19$503
Mirtazapine50$464
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine26$435

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$57$7,97915 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,344 psychiatry providers in Illinois.

Other psychiatry in Maywood

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →